InvestSMART

Clinuvel Pharmaceuticals Limited (ASX:CUV)

ALERT: Price-sensitive ASX Announcement for CUV
Current share price for CUV : $9.920 0.94 (10.47%)+
Announcement
Release
28 Apr 2026 8:50AM
Price at Release
$8.980
Full Release
download
Summary
Clinuvel Pharmaceuticals Limited announced its engagement with the U.S. Securities and Exchange Commission (SEC) concerning its draft registration statement for upgrading its American Depository Receipt (ADR) program from Level I to Level II on the Nasdaq Stock Market. The company has addressed four rounds of inquiries from the SEC and anticipates completing the review before the end of the 2026 financial year, concluding on 30 June 2026. Post-review, Clinuvel aims to list its ADR on Nasdaq under the ticker CUVL, although no final decision has been made, as it remains contingent on SEC review and Nasdaq listing requirements. Clinuvel will continue to update the market on significant developments. This strategic move aligns with Clinuvel's focus on developing treatments for genetic and systemic acute disorders and expanding its market presence globally.
Key Points
  • Clinuvel engaging with SEC for ADR upgrade
  • Expected completion of SEC review by June 2026
  • Plan to list on Nasdaq as CUVL post-SEC review
  • No final decision on uplisting; subject to SEC and Nasdaq requirements
  • Clinuvel's focus on innovative treatments and global expansion
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.